01:40 AM EDT, 10/22/2026 (MT Newswires) -- Argenx (ARGX.BR) logged $506 million in profit attributable to owners of the parent for the third quarter, compared with $344 million a year ago. EPS moved to $7.80 from $5.18 year over year, a Thursday filing showed. For the three months ended Sept. 30, product net sales were $1.72 billion versus $1.13 billion previously, the immunology company added.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.